8月 2026Erasca的市場佔有率分析

Privacy policy Last Updated: May 28, 2026 This Privacy Policy describes the privacy practices of Erasca, Inc. (“Erasca”, “we”, “us” or “our”). Protecting the privacy and security of your personal information is important to Erasca. This Privacy Policy is designed to help you understand what data Erasca may collect, how Erasca uses and safeguards that […]

健康 > 生物技術和製藥

域名erasca.com

成立年份2018

僱員51 - 200

年度營收$25M - $50M

Erasca

Erasca（包含公司地區）

erasca.com

查看更多網站流量與參與度資訊

Erasca截至 8月 2026 的總收入為 25M - 50M

Erasca 熱門網域產生的總收入

Erasca 熱門網域 3 年內的總收入

Erasca 熱門網域的總收入

erasca.com25M - 50M

透過銷售情報查看更多內容

Erasca的熱門網域總造訪量

了解Erasca市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

erasca.com8.8K

透過銷售情報查看更多內容

Erasca的熱門網域平均造訪時長

分析Erasca參與度指標。

過去 3 個月平均造訪時長

子公司細目

erasca.com00:00:26

透過銷售情報查看更多內容

Erasca的熱門網域平均頁面瀏覽量

了解Erasca如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

erasca.com1.86

透過銷售情報查看更多內容

Erasca按網域劃分的熱門競爭對手

8月 2026的熱門類似網站，依相似度排名

kuraoncology.com公司名Kura Oncology僱員51 - 200總部美國, 加利福尼亞, San Diego年度營收$25M - $50M訪問總量21.2K健康 > 生物技術和製藥

使用的熱門技術Erasca

这些是Erasca顶级域名使用的行业网站技术

行動裝置 (3)

Meta Viewport

小工具 (3)

Twemoji

市場行銷 (2)

Google Marketing Platform

付費廣告 (1)

DoubleClick

更多技術

8

檢視所有

新聞與訊號來自Erasca

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Erasca, Inc. hired Charles S. Fuchs as president of research and development on Aug 10th '26.SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) - Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that, in connection with the appointment of Charles S. Fuchs, M.D., M.P.H., as president of research and development, Erasca's Board of Directors has approved the grant of inducement awards.

新聞Erasca, Inc. has issues with class action lawsuit.Erasca faces class action lawsuit, stock takes hit.

新聞Erasca, Inc. had issues with securities fraud or other unlawful business practices on Jul 7th '26.The class action concerns whether Erasca and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.